Check-CapSTU:7CC -0.93%27 Pretax Margin % is % as of Dec. 2025. GuruFocus rates STU:7CC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Check-Cap ranks worse than 495049.01% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Check-Cap's Pre-Tax Income for the
six
months ended in Dec. 2025 was €-0.92 Mil. Check-Cap's Revenue for the
six
months ended in Dec. 2025 was €0.00 Mil. Therefore, Check-Cap's pretax margin for the quarter that ended in Dec. 2025 was %.
The historical rank and industry rank for Check-Cap's Pretax Margin % or its related term are showing as below:
STU:7CC's Pretax Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -3.565 * Ranked among companies with meaningful Pretax Margin % only.
Check-Cap (STU:7CC) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Check-Cap Pretax Margin % Related Terms
Check-Cap Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Check-Cap's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7CC vs ADVB, XWEL, NDRA: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Check-Cap's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Check-Cap Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Check-Cap's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Check-Cap (STU:7CC) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Check-Cap and its competitors. According to the industry distribution chart, Check-Cap ranks #999999 out of 202 companies in the Medical Diagnostics & Research industry.
Is Check-Cap's Pretax Margin % too high?
Check-Cap's current Pretax Margin % is %. Based on the distribution chart, Check-Cap ranks #999999 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Check-Cap has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's Pretax Margin % compare to ADVB and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #999999 out of 202 companies for Pretax Margin %. This places Check-Cap in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Check-Cap and its competitors. Check-Cap's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current Pretax Margin % of %. The current Pretax Margin % is %. Check-Cap's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
27GF Score
Get the complete analysis for STU:7CC
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CC has been successfully added to your 
